Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

doi:10.21203/rs.3.rs-1523740/v1

Download PDF

Research Article

Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

https://doi.org/10.21203/rs.3.rs-1523740/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Chemotherapy-induced neutropenia (CIN) is a dose-limiting factor for cytotoxic chemotherapy, but recently, it was suggested that CIN contributes to prolonged survival. In this study, we examined the association between severe CIN and survival, and determined whether CIN affected survival in patients with extensive-stage small cell lung cancer (ED-SCLC).The medical records from 214 patients with ED-SCLC treated with etoposide or irinotecan in combination with cisplatin (EP/IP) between 2012 and 2016 were collected and retrospectively analyzed. Landmark analysis was performed at the end of cycle 4 and the relationship between severe CIN and survival was determined by a log-rank test. In addition, a multivariate analysis using COX proportional hazard model was performed to identify independent predictive factors. The Landmark analysis included 102 patients in the IP-group and 47 patients in the EP-group. No significant difference was found between grade 0–3 and grade 4 neutropenia and overall survival (OS) in the EP-group. (P = 0.57). Contrariwise, for the IP patients, the median OS was 444 days for grade 0–3 and 633 days for grade 4 neutropenia, which was significantly longer for patients who developed grade 4 neutropenia (P = 0.03). Multivariate analysis adjusted for potential factors revealed that the development of grade 4 CIN was identified as a significant predictor of longer OS (hazard ratio [HR], 0.46; 95% confidence interval (CI), 0.26–0.81, P = 0.008). The results indicated that the development of severe CIN with IP therapy is associated with prolonged OS.

Chemotherapy-induced neutropenia

small cell lung cancer

etoposide

irinotecan

cisplatin

Lung cancer remains the leading cause of cancer deaths worldwide including Japan. Small cell lung cancer (SCLC) accounts for 10–15% of all lung cancers and is biologically, molecularly, and clinically very different from other lung cancers.[1] Although SCLC is more sensitive to chemotherapy and radiotherapy compared with other lung cancers, it recurs in most cases. SCLC may be classified into two types: limited disease and extensive disease (ED). ED-SCLC is a refractory disease with a poor prognosis and a 5-year survival rate of less than 5%.[2]

Cisplatin combined with etoposide (EP) or irinotecan (IP) are two of the most commonly used chemotherapeutic regimens for first-line treatment of ED-SCLC. In particular, IP is widely used in Japan as first-line treatment based on the results of a Japanese phase III trial (JCOG 9511) and a meta-analysis including this clinical trial.[3–5]

Chemotherapy-induced neutropenia (CIN) is a significant dose-limiting toxicity for many cytotoxic anticancer drugs, but an interesting association between the occurrence of CIN and a favorable clinical outcome has been reported in several solid tumors.[6–10] In lung cancer, post-hoc analyses of clinical trials for non-small cell lung cancer have also reported that the occurrence of CIN contributes significantly to prolonged survival.[11]^,[12] However, because of the limited number of SCLC cases, few studies have been conducted thus far to evaluate the prognostic role of CIN in patients with ED-SCLC. Furthermore, the JCOG 9511 study conducted in Japan for ED-SCLC revealed a high incidence of CIN.[3] Intriguingly, the incidence of severe CIN was higher compared with that reported in the non-Asians studies,[13]^,[14] and thus the relationship between the development of severe CIN and survival is an important issue study. Therefore, we conducted a multicenter study in Japanese patients to determine the association between severe CIN development and survival in patients with ED-SCLC treated with IP or EP therapy.

Data source and data collection

Patients diagnosed with ED-SCLC during the 5-year period from January 1, 2012 to December 31, 2016 at 14 study sites in Japan were included. Patients aged 20 years or older who received cisplatin-based chemotherapy as first-line treatment were eligible. The regimens included in this study were IP (intravenous cisplatin 60 mg/m² on day 1 and irinotecan 60 mg/m² on days 1, 8, and 15, every 28 days) and EP (intravenous cisplatin 80 mg/m² on day 1 and etoposide 100 mg/m² on days 1 through 3, every 21 days), which are standard therapies for ED-SCLC.

The exclusion criteria were as follows: 1) Patients without distant metastasis; 2) Patients who received a chemotherapy regimen other than IP or PE as initial therapy; and 3) Patients who received primary prophylactic administration of granulocyte colony-stimulating factor (G-CSF). Clinical records of patients with ED-SCLC receiving IP or PE therapy were extracted from the electronic medical records system maintained by each institution and retrospectively reviewed. Clinical parameters included age, sex, BMI, number of metastasis sites, baseline biochemical and hematological data, secondary prophylactic use of G-CSF, and the date of confirmed recurrence or death from any cause.

Patients and treatments

Patients who received standard doses of IP or EP as initial therapy for advanced and previously untreated SCLC were selected from the electronic medical record system of each participating institution. A total of 214 patients were selected and divided into two groups: those who received IP (n = 138) and those who received EP (n = 76).

Clinical data and assessment of CIN

Clinical data including patient characteristics and prognostic factors were collected from each hospital’s electronic medical records. Hematologic toxicity was assessed based on the Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0). CIN grade was determined based on the lowest neutrophil count for each patient recorded during first-line treatment. The endpoint of the study was severe CIN survival. This was defined as the time from the start date of cisplatin-based chemotherapy to the date of death or the last day of the follow-up period.

Statistical analysis

Neutropenia occurring during the treatment period was graded (grade 0–4) according to CTCAE v5.0. Survival curves for overall survival (OS) were generated for each grade of neutropenia using the Kaplan–Meier method and compared using the log-rank test. To analyze the effect of severe CIN development on clinical outcomes in patients with ED-SCLC, a multivariate analysis was performed using the COX proportional hazards model. Hazard ratios and 95% confidence intervals were calculated. A multivariate analysis with a P value < 0.05 was considered statistically significant. In this study, Landmark analysis[15] was performed and patients who died within 112 days (equivalent to 4 cycles of IP) or 84 days (equivalent to 4 cycles of EP) of starting IP or EP, and patients who received less than 4 cycles of IP or EP, were excluded from the analysis. Patients with distant metastatic cancer may die early during chemotherapy, and these patients may receive less chemotherapy, which reduces the likelihood of developing CIN. In other words, patients with longer survival receive more chemotherapy are more likely to develop CIN, which may lead to a large bias in the association of CIN with prolonged survival. To avoid this bias, we performed a Landmark analysis. Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM Japan Ltd. Tokyo, Japan) and EZR version 1.55.[16]

Patient characteristics

A total of 214 patients with a diagnosis of ED-SCLC were selected from the electronic medical record system at each participating hospital. Of 138 patients who received IP, 35 patients received less than the planned four cycles of chemotherapy (112 days) or received four cycles, but died within 112 days, whereas 1 patient with missing neutrophil count data was excluded. Of the 76 patients who received EP, 28 patients received less than four cycles (84 days) or received four cycles, but died within 84 days and were excluded. One patient with missing neutrophil count data was also excluded. A flow diagram of the patients who participated in the study is shown in Fig. 1 and the baseline and clinical characteristics are listed in Table 1. In the Landmark analysis, 84 of the 102 patients who received IP therapy died. Of the 47 patients who received EP, 43 died.

Table 1

Baseline demographics and clinical characteristics of the study patients
Characteristic	Patients treated IP N (%), median (range)	Patients treated EP N (%), median (range)
Gender
Male	81 (79.4)	45 (95.7)
Female	21 (20.6)	2 (4.3)
Age (y)	64 (44–76)	68 (52–76)
ECOG PS
0	37 (44)	22 (50.0)
1	40 (47.6)	22 (50.0)
2	7 (8.3)	0 (0.0)
Complications
Yes	66 (64.7)	33 (70.2)
No	36 (35.3)	14 (29.8)
Number of metastatic sites
< 3	17 (16.7)	38 (80.9)
≥ 3	85 (83.3)	9 (19.1)
History of febrile neutropenia
Yes	9 (8.8)	9 (19.1)
No	93 (91.2)	38 (80.9)
LDH (IU/L)	260.5 (3.5–5652)	256.0 (169–549)
Neutrophil count (/mm³)	4745 (2080–10846)	4477 (600–19845)

Abbreviations: ECOG PS = Eastern Cooperative Oncology Group Performance status; LDH = lactate dehydrogenase

Incidence of CIN

Of the 102 patients who received IP chemotherapy, 89.2% (n = 91) experienced CIN, of which 13.7% (n = 14) were grade 1, 28.4% (n = 29) were grade 2, 25.5% (n = 26) were grade 3, and 22.5% (n = 23) were grade 4. Of the 47 patients who received EP therapy, 95.7% (n = 45) experienced CIN, of which 2.1% (n = 1) were grade 1, 6.3% (n = 3) were grade 2, 25.5% (n = 12) were grade 3, and 61.7% (n = 29) were grade 4.

Relationship between OS and CIN

Of the 102 patients who received IP therapy, 84 were confirmed dead by the time of the analysis, and 18 were censored or lost to follow-up. Two groups were compared: the severe CIN group (grade 4) and the absent/mild CIN group (grade ≤ 3). Figure 2 shows the cumulative OS curves of the severe CIN group and the absent/mild CIN group. The median survival time was approximately 1.5 times longer in the severe CIN group compared with the absent/mild CIN group (633 days [95% CI, 379–757] vs. 444 days [95% CI, 360–505]; P = 0.028).

Of the 47 patients who received EP therapy, 43 were confirmed dead by the time of the analysis and 4 were censored or lost to follow-up. Two groups were compared: the severe CIN group and the absent/mild CIN group. Figure 3 shows the cumulative OS curves of the severe CIN group and the absent/mild CIN group. There was no statistically significant difference in median survival time between the two groups (443 days [95% CI, 281–533] vs. 411 days [95% CI, 331–568]; P = 0.670, respectively). Univariate analysis suggests that severe CIN is associated with prolonged OS in patients treated with IP. To evaluate whether severe CIN is an independent prognostic factor, we performed a multivariate analysis that incorporated CIN (grade 0–3 vs. grade 4), gender, age, LDH, and the number of metastatic sites, which have been reported to be associated with prognosis in ED-SCLC as independent variables.[17]^,[18] A COX proportional hazards regression analysis was performed using the forced entry method. A multivariate analysis revealed that LDH ≥ 245 (hazard ratio [HR], 3.08; 95% CI, 1.88–5.04; P < 0.001) and grade 4 CIN (HR, 0.46; 95% CI, 0.26–0.81; P = 0.008) were prognostic factors (Table 2). The same results were confirmed in a stepwise analysis (LDH ≥ 245 (HR, 3.17; 95% CI, 1.95–5.17; P < 0.001), grade 4 CIN (HR, 0.49; 95% CI; 0.28–0.85; P = 0.012)).

Table 2

Multivariate analyses of the association between grade 4 neutropenia and clinical variables
Characteristic		HR (95% CI)	P value
CIN	Grade 0–3	1	0.008
	Grade 4	0.46 (0.26–0.81)	0.008
Gender	Male	1	0.909
	Female	1.03 (0.58–1.83)	0.909
Age (y)	< 65	1	0.218
	≥ 65	1.34 (0.84–2.13)	0.218
LDH (IU/L)	< 245	1	< 0.001
	≥ 245	3.08 (0.84–5.04)	< 0.001
Number of metastatic sites	< 3	1	0.087
	≥ 3	1.73 (0.92–3.24)	0.087
Abbreviations: CIN = Chemotherapy-induced neutropenia; HR = Hazard ratio; CI = Confidence interval; LDH = lactate dehydrogenase

In this study, we examined the relationship between OS and the occurrence of severe CIN to identify prognostic factors for patients with ED-SCLC that were treated with standard IP or EP as first-line therapy. A multivariate analysis revealed that pretreatment LDH levels ≥ 245 and grade 4 CIN were two significant independent factors that influenced the OS of patients treated with IP. LDH has long been reported to be a prognostic factor in solid tumors and it has also been reported to be a prognostic factor in SCLC.[17] This finding was consistent with the results of the current study and confirmed LDH as an important prognostic factor. We also showed that in addition to LDH, the occurrence of severe CIN was an independent factor affecting the prognosis of patients with ED-SCLC treated with IP.

In recent years, an integrated analysis of 6 randomized clinical trials in non-SCLC revealed that the occurrence of severe CIN has a positive impact on prognosis.[19] CIN is not just an adverse event, but may serve as a marker of improved patient outcome. The development of grade 4 neutropenia in patients treated with IP was also associated with longer OS in our study. Although the detailed mechanism of the association between the development of severe CIN and favorable prognosis is unclear, it is believed that the hematological toxicity associated with the administration of cytotoxic drugs may be a surrogate marker for the biological activity of anticancer drugs.[20] Since hematologic toxicity, such as neutropenia, is a dose-dependent adverse event, patients who do not develop CIN may have received inadequate doses of the anticancer drugs or may be resistant to treatment.[21] Currently, the dose of anticancer drugs is administered to the patient based on body surface area (BSA) or creatinine clearance,[22] however, it has been suggested that BSA-based dosing calculations may be inadequate.[23] In two randomized trials of gastric and breast cancer, a trend toward improved progression-free and recurrence-free survival were observed in the latter group compared with the BSA-based dosing chemotherapy group and the group in which the dose of anticancer drugs was adjusted based on the incidence of adverse reactions, such as CIN.[24] Although no studies have been conducted in SCLC, this retrospective study revealed that grade 4 CIN may be an indicator of IP response. In other words, low grade CIN results from an underdose of IP therapy, and prognosis may be improved by increasing the dose of the anticancer drugs. However, there is currently insufficient evidence for dose escalation for IP therapy in patients with SCLC, thus it is necessary to conduct prospective clinical trials to evaluate dose escalation and safety.

In contrast, there was no association between the development of CIN and prolonged survival in patients who received EP therapy as opposed to IP therapy. A high incidence of grade 3 or higher CIN was associated with EP therapy (92.2%) in a phase III trial of Japanese patients with ED-SCLC.[3] In the present study, we found that grade 3 or higher CIN occurred more frequently in the EP therapy (87.2%) group, in particular, 61.7% of the patients had grade 4 CIN. The incidence of FN in the group of patients who received EP therapy was 19.1% (9/47), which was higher compared with that of patients who received IP therapy (4.9%, 5/102). Thus, the occurrence of FN may have had a significant effect as a poor prognostic factor in patients treated with EP. In fact, the MST was 473 days (95% CI, 371–599) for the group without FN and 367 days (95% CI, 219–443) for the group with FN (log-rank, P = 0.040).

To our knowledge, there have been no studies on the relationship between the occurrence of CIN and ED-SCLC patient survival. This study showed for the first time that the occurrence of CIN is not associated with prognosis following EP therapy and the development of severe CIN is associated with a favorable prognosis following IP therapy. Irinotecan is converted to its active metabolite, SN-38, by carboxylesterases. SN-38 is inactivated and excreted into the bile by glucuronidation, which is catalyzed by UDP-glucuronosyltransferases.[25] Since irinotecan and SN-38 are both substrates for the ABC transporters, polymorphisms in these transporter genes may affect the pharmacokinetics of irinotecan and irinotecan-associated toxicity. The association between the development of CIN and polymorphisms in the UGT1A1 and ABCB1 genes is becoming clearer.[26–28] It is anticipated that the prediction of response to IP therapy will be possible by examining these genetic polymorphisms prior to chemotherapy.

Recently, a three-drug combination chemotherapy regimen consisting of platinum and etoposide plus an immune checkpoint inhibitor (ICI) has been recommended as a standard regimen for ED-SCLC. The results of two phase III trials indicated the efficacy of triplet chemotherapy with atezolizumab or durvalumab, showing a median OS time of 12.3 and 12.9 months, respectively, for patients treated with ICIs.[29]^,[30] The median OS of all patients treated with IP in this study was 423 days (approx.14.1 months), whereas the median OS of patients who developed grade 4 CIN was 555 days (approx. 18.5 months). Although a simple comparison cannot be made, the median survival time of patients treated with IP therapy is comparable to that of combined therapy with platinum, etoposide, and ICI. Moreover, there appears to be a clear trend toward improved median survival time, particularly in patients who developed grade 4 CIN. Combination chemotherapy regimens with ICI and anticancer drugs have been implemented worldwide for multiple cancer types, however, combination therapy with atezolizumab or durvalumab has been estimated to be less cost effective compared with conventional chemotherapeutic regimens for first-line treatment of patients with ED-SCLC.[31]^,[32] In addition, biomarkers for predicting the effect of ICIs, such as PD-L1 expression and tumor mutational burden, have not been established in ED-SCLC.[33] Therefore, the selection of responders may be an important therapeutic strategy in conventional chemotherapy, in which the cost of treatment is relatively low.

There are several limitations to the current study. First, this was a retrospective study and the sample size was not determined. Also, the patients were Japanese and it has been suggested that there are differences in the development of CIN based on race. Thus, the findings of this study may not be applicable to patients in other countries or regions of Japan. Despite these limitations, the results of this study are important because they are the first to show that the occurrence of severe CIN with IP therapy is a prognostic factor for ED-SCLC and revealed that median OS is extremely long in patients exhibiting severe CIN.

Severe CIN is a useful prognostic factor for ED-SCLC patients treated with IP therapy, but not EP therapy. These findings suggest that severe CIN may be used as a marker to predict a good clinical response to IP therapy in patients with ED-SCLC. Furthermore, if CIN can be predicted prior to the initiation of chemotherapy, physicians may be able to stratify patients receiving IP chemotherapy and monitor neutrophil counts and patient status. It may possible to identify the ED-SCLC patients who are expected to have a longer survival. It is also anticipated that the use of prediction models for CIN will lead to individualized treatment for ED-SCLC.

Author contribution

Conception and design were performed by DT, TM, YK and KY. Acquisition of data was carried out by HI, RT, MN, SN, THay, HA, THar, ST, AM, YO, YA, YF, KY, YM and TY. Statistical analysis and interpretation of the data were carried out by TM, DT and YK. Drafting of the article was carried out by DT, TM, and KI. All authors read and approved the final manuscript.

Funding

This work was supported in part by the University of Shizuoka academic research grant. The authors have not received any funding or benefits from industry or elsewhere to conduct this study.

Availability of data and material

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest

The authors have declared that they have no conflict of interest regarding this study.

Ethical approval

The study protocol was approved by the ethics committee of each participating institution and conducted in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards and with the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan.

Consent to participate

As this was a retrospective study, written informed consent to participate was not obtained. Instead, we offered the patients the right to opt out.

Sawabata N, Asamura H, Goya T, Mori M, Nakanishi Y, Eguchi K, et al. Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002. J Thorac Oncol Elsevier. 2010;5:1369–75.
Oze I, Ito H, Nishino Y, Hattori M, Nakayama T, Miyashiro I, et al. Trends in Small-Cell Lung Cancer Survival in 1993–2006 Based on Population-Based Cancer Registry Data in Japan. J Epidemiol [Internet]. Japan Epidemiology Association; 2019 [cited 2021 Jan 28];29:347–53. Available from: https://www.jstage.jst.go.jp/article/jea/29/9/29_JE20180112/_article.
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. N Engl J Med [Internet] Massachusetts Medical Society. 2002;346:85–91. [cited 2021 Jan 28];. Available from: www.nejm.org.
Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol International Association for the Study of Lung Cancer. 2010;5:867–73.
Liu ZL, Wang B, Liu JZ, Liu WW. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis. J Cancer Res Ther [Internet]. Medknow Publications and Media Pvt. Ltd.; 2018 [cited 2021 Dec 7];14:1076. Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2018;volume=14;issue=12;spage=1076;epage=1083;aulast=Liu.
Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997 752 [Internet]. Nature Publishing Group; 1997 [cited 2021 Dec 7];75:301–5. Available from: https://www.nature.com/articles/bjc199749.
Cameron DA, Massie C, Kerr G, Leonard RCF. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer [Internet]. Br. J. Cancer. Nature Publishing Group; 2003 [cited 2021 Jan 28]. p. 1837–42. Available from: www.bjcancer.com.
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007 971 [Internet]. Nature Publishing Group; 2007 [cited 2021 Jul 15];97:37–42. Available from: https://www.nature.com/articles/6603831.
Otake A, Tsuji D, Taku K, Kawasaki Y, Yokoi M, Nakamori H, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. Eur J Clin Pharmacol [Internet]. Springer Verlag; 2017 [cited 2021 Jan 28];73:1033–9. Available from: https://link.springer.com/article/10.1007/s00228-017-2260-0.
Yamamoto K, Sasano T, Tsuji D, Ishizuka Y, Tokou U, Nakamichi H, et al. A Retrospective Analysis of the Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy. Ann Pharmacother [Internet]. SAGE Publications Inc.; 2019 [cited 2021 Dec 7];53:690–6. Available from: https://journals.sagepub.com/doi/10.1177/1060028019830785?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed.
Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol Elsevier. 2005;6:669–77.
Kishida Y, Kawahara M, Teramukai S, Kubota K, Komuta K, Minato K, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: Results from Japan Multinational Trial Organization LC00-03. Br J Cancer [Internet] Nature Publishing Group. 2009;101:1537–42. [cited 2021 Jan 28 ;:. Available from: www.bjcancer.com.
Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1. Cancer [Internet]. John Wiley & Sons, Ltd; 2010 [cited 2021 Dec 7];116:5710–5. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25532.
Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2009 [cited 2021 Jan 25];27:2530–5. Available from: /pmc/articles/PMC2684855/?report = abstract.
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol American Society of Clinical Oncology. 2008;26:3913–5.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2013 [cited 2021 Jan 28];48:452–8. Available from: http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/.
Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, et al. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer [Internet] Nature Publishing Group. 2015;112:1709–16. [cited 2021 Jan 28];. Available from: www.ClinicalTrials.gov.
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet [Internet]. Springer International Publishing; 2018;57:1229–54. Available from: https://doi.org/10.1007/s40262-018-0644-7.
Gargiulo P, Arenare L, Gridelli C, Morabito A, Ciardiello F, Gebbia V, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer 2021 211 [Internet]. BioMed Central; 2021 [cited 2021 Jul 9];21:1–9. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08323-4.
Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 1999 8011 [Internet]. Nature Publishing Group; 1999 [cited 2021 Dec 7];80:1681–1681. Available from: https://www.nature.com/articles/6690583.
Kan M, Imaoka H, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol 2020 862 [Internet]. Springer; 2020 [cited 2021 Jul 15];86:203–10. Available from: https://link.springer.com/article/10.1007/s00280-020-04110-3.
Newell DR. Getting the right dose in cancer chemotherapy – time to stop using surface area? Br J Cancer 2002 868 [Internet]. Nature Publishing Group; 2002 [cited 2021 Jul 15];86:1207–8. Available from: https://www.nature.com/articles/6600226.
Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002 868 [Internet]. Nature Publishing Group; 2002 [cited 2021 Jul 15];86:1297–302. Available from: https://www.nature.com/articles/6600139.
Foukakis T, Minckwitz G von, Bengtsson N-O, Brandberg Y, Wallberg B, Fornander T, et al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA [Internet]. American Medical Association; 2016 [cited 2021 Jul 13];316:1888–96. Available from: https://jamanetwork.com/journals/jama/fullarticle/2579866.
Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res. 1997;3.
Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, et al. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. Eur J Cancer Pergamon. 2018;99:66–77.
Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemother Pharmacol [Internet]. Springer Verlag; 2017 [cited 2021 Dec 7];80:135–49. Available from: https://link.springer.com/article/10.1007/s00280-017-3344-3.
Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, et al. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J [Internet]. Nature Publishing Group; 2018 [cited 2021 Jan 28];18:35–42. Available from: https://www.nature.com/articles/tpj201675.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med [Internet]. New England Journal of Medicine (NEJM/MMS); 2018 [cited 2021 Dec 7];379:2220–9. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1809064.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol Elsevier. 2021;22:51–65.
Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer Elsevier. 2019;130:1–4.
Tong YH, Ding HY, Xin WX, Zhong LK, Xu GQ, Zhang B, et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers’ perspective. Tumori [Internet]. SAGE Publications Ltd; 2021 [cited 2021 Dec 7]; Available from: https://journals.sagepub.com/doi/10.1177/0300891620985309?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed.
Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol 2020 175 [Internet]. Nature Publishing Group; 2020 [cited 2021 Dec 7];17:300–12. Available from: https://www.nature.com/articles/s41571-019-0316-z.

Download PDF

Version 1

posted

You are reading this latest preprint version

Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

Status:

Version 1

Abstract

Figures

Introduction

Materials And Methods

Data source and data collection

Patients and treatments

Clinical data and assessment of CIN

Statistical analysis

Results

Patient characteristics

Incidence of CIN

Relationship between OS and CIN

Discussion

Conclusion

Declarations

References

Status:

Version 1